Search Patents
  • CORONAVIRUS VACCINE
    Publication number: 20240042011
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 20, 2023
    Publication date: February 8, 2024
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin
  • Anti-Coronavirus Antibodies and Methods of Use
    Publication number: 20240150438
    Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Application
    Filed: March 31, 2023
    Publication date: May 9, 2024
    Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
  • CORONAVIRUS VACCINE
    Publication number: 20230338512
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: November 29, 2022
    Publication date: October 26, 2023
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai
  • Anti-coronavirus antibodies and methods of use
    Patent number: 11370828
    Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: June 28, 2022
    Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
  • Anti-coronavirus antibodies and methods of use
    Patent number: 11447541
    Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: September 20, 2022
    Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
  • MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES
    Publication number: 20240066114
    Abstract: The present invention is inter alia directed to compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus membrane protein (M), nucleocapsid protein (N), non-structural protein, and/or accessory protein or an immunogenic fragment or immunogenic variant thereof. The composition may additionally comprise at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus spike protein (S). The nucleic acid sequences of the compositions are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The compositions provided herein are for use in treatment or prophylaxis of an infection with at least one Coronavirus, and may therefore be comprised in a vaccine, preferably a multivalent vaccine.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 29, 2024
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Nicole ROTH, Benjamin PETSCH, Wolfgang GROSSE
  • A LIVE ATTENUATED MEASLES VIRUS VECTORED VACCINE FOR SARS-COV-2
    Publication number: 20230310581
    Abstract: Disclosed herein is a live attenuated recombinant measles virus (rMeV)-based coronavirus vaccine containing a SARS-CoV-2 spike (S) protein that has at least one mutation to remove a glycosylation site. In some embodiments, the rMeVs-based coronavirus vaccine contains full-length stabilized pre-fusion and native S proteins, S proteins of SARS-CoV-2 variants, truncated S proteins lacking its transmembrane and cytoplasmic domains, S proteins lacking glycosylation sites, the monomeric and trimeric receptor-binding domain (RBD), the monomeric and trimeric S1 protein, Fc-fused RBD, or Fc-fused S1 protein. Also disclosed is a live attenuated recombinant coronavirus vaccine, wherein a stabilized prefusion spike (S) protein is inserted into a viral vector genome.
    Type: Application
    Filed: April 27, 2021
    Publication date: October 5, 2023
    Inventors: Jianrong LI, Stefan NIEWIESK, Anzhong LI, Mijia LU
  • TREATING SAR-COV-2 RELATED HEALTH PROBLEMS
    Publication number: 20230190703
    Abstract: A method of treating Sar-cov-2 re-infection in a subject, a method of reducing side effects in a subject suffering from side effects of Covid-19 vaccination, a method of reducing apoptosis of immune cells or gut cells caused by a Sar-cov-2 spike protein in a subject, a method of reducing necrosis of immune cells or gut cells caused by a Sar-cov-2 spike protein in a subject, a method of increasing CD26 level in immune cells in a subject infected with Sar-cov-2, and a method of decreasing cell adhesion molecule level in immune cells in a subject infected with Sar-cov-2 are disclosed. Each method comprises administering an effective amount of a pharmaceutical composition comprising artemisinin or artesunate to said subject. A method of making an anti-Sar-cov-2 compound by making and testing derivatives artemisinin or artesunate is disclosed.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 22, 2023
    Inventor: Allen Qian
  • SARS-COV-2 NEUTRALIZING ANTIBODY OR FRAGMENT THEREOF
    Publication number: 20230348573
    Abstract: An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 2, 2023
    Applicants: KEIO UNIVERSITY, JAPAN as represented by DIRECTOR GENERAL of NATIONAL INSTITUTE OF INFECTIOUS DISEASES, RIKEN, SHIGA UNIVERSITY OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO
    Inventors: Masaru TAKESHITA, Tsutomu TAKEUCHI, Katsuya SUZUKI, Hideyuki SAYA, Yoshimasa TAKAHASHI, Saya MORIYAMA, Hidehiro FUKUYAMA, Chieko OKAMURA, Mikako SHIROUZU, Takehisa MATSUMOTO, Katsuhiko KAMADA, Yasushi ITOH, Hirohito ISHIGAKI, Misako NAKAYAMA, Yoshinori KITAGAWA, Yoshihiro KAWAOKA
  • CORONAVIRUS VACCINE
    Publication number: 20230075979
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 18, 2022
    Publication date: March 9, 2023
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • METHODS AND COMPOSITIONS FOR INCREASING IMMUNITY AGAINST CORONAVIRUSES
    Publication number: 20230285541
    Abstract: The disclosure provides methods and compositions for increasing immunity against coronaviruses, in particular highly pathogenic coronaviruses. Compositions are provided comprising peptides comprising at least a part of the S2 ectodomain of the S (spike) protein from at least one human coronaviruses (HCoV) selected from HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1, as well as compositions comprising nucleic acid molecules encoding at least a part of the S2 ectodomain of the S (spike) protein from at least one human coronaviruses (HCoV) selected from HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1. Compositions described herein are particularly useful as vaccines, in particular against highly pathogenic coronaviruses such as SARS-CoV-1, MERS-CoV and/or SARS-CoV-2 as well as cross-species transmission of typically non-human coronaviruses.
    Type: Application
    Filed: July 20, 2021
    Publication date: September 14, 2023
    Inventors: Domenico VALERIO, Jaap GOUDSMIT, Stefan Frederik Franciscus VERLINDEN
  • CORONAVIRUS VACCINE
    Publication number: 20230073461
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 18, 2022
    Publication date: March 9, 2023
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE
    Publication number: 20230398206
    Abstract: The invention relates to a method of eliciting an immune response in a human subject showing no signs or symptoms of an active SARS-CoV-2 infection comprising administering intra-dermally to the human subject an immunogenic composition comprising the Spike protein (S protein) of SARS-CoV-2 or a fragment thereof.
    Type: Application
    Filed: October 27, 2021
    Publication date: December 14, 2023
    Inventors: David Berd, James Passin
  • PEPTIDE BASED PROBES FOR THE DETECTION OF SARS-COV-2
    Publication number: 20230194525
    Abstract: A highly specific molecular diagnostic for the detection of an intended target protein within a matter of minutes employing a peptide beacon, the peptide beacon having a stem section having two ends attached to a fluorophore and a quencher and a loop section having a receptor sequence for binding with the intended target protein, the two ends forming a coiled-coil structure when the receptor sequence is unbound with the intended target protein and an open-coil structure when the receptor sequence is bound with the intended target protein, wherein the peptide beacons are able to provide a signal for the detection of the receptor binding domain of the intended target protein, such as SARS-CoV-2 spike protein, by the stem section transitioning from the coiled-coil structure to the open-coil structure that moves the fluorophore away from the quencher, resulting in an increase in the fluorescence yield of the peptide beacon.
    Type: Application
    Filed: April 29, 2022
    Publication date: June 22, 2023
    Inventors: Pranam CHATTERJEE, Raghava Manvitha PONNAPATI, Soumya Pratap TRIPATHY, Joseph M. JACOBSON
  • Coronavirus vaccine
    Patent number: 11547673
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: January 10, 2023
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • COMPUTING SYSTEM AND METHOD OF DETERMINING TARGET EPITOPE ON SPECIFIC VIRUS FOR FACILITATING DESIGN OF MUTATION-TOLERABLE VACCINE
    Publication number: 20230099381
    Abstract: A method includes: determining a mutation frequency for each residue in a wild-type spike protein of a specific virus; for each residue in the protein, counting a total number of contact residues related to said each residue and P antibodies based on P entries of protein structure data; for each residue in the protein, for a condition that said each residue mutates into one common amino acid residue, determining a normalized binding free energy value using a pre-established model based on the protein structure data, and determining a mutation effect score based on the mutation frequency, the total number of contact residues and the normalized binding free energy value; generating a mutation effect epitope map related to the mutation effect scores determined for all residues in the protein and all common amino acid residues; and determining, based on the map, a region in the protein as a target epitope.
    Type: Application
    Filed: September 23, 2022
    Publication date: March 30, 2023
    Inventors: Yi-Ting CHEN, Sing-Han HUANG, Ching-Yung LIN, Xiang-Yu LIN, Cheng-Tang WANG
  • METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH SARS-COV-2
    Publication number: 20240025972
    Abstract: Provided herein are methods of treating or preventing SARS-CoV-2 infection comprising modulating interactions between the SARS-CoV-2 spike protein and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.
    Type: Application
    Filed: May 22, 2023
    Publication date: January 25, 2024
    Inventor: Nadia MARTINEZ-MARTIN
  • SARS-CoV-2 polypeptide inhibitors directed against the Env TM domain and methods of treatment using said inhibitors
    Patent number: 11548919
    Abstract: Methods for treating coronavirus infection, such as an infection caused by SARS-CoV-2, in a subject in need thereof include administering to the subject a therapeutically effective amount of a composition comprising an isolated polypeptide targeting the spike protein and the transmembrane region of the coronavirus envelope protein. Compositions include isolated polypeptides complementary to residues 30-38 of the envelope protein transmembrane region.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: January 10, 2023
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Alaa F. Nahhas, Thomas Webster
  • CORONAVIRUS VACCINE
    Publication number: 20240075165
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 7, 2024
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • Coronavirus vaccine
    Patent number: 11925694
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 12, 2024
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
Narrow Results

Filter by US Classification